Clinical Trial Update: GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients [NA]

View source ↗

Summary

The GCC 1366 trial evaluating anti-proliferative response to neoadjuvant aromatase inhibitors in overweight and obese breast cancer patients was terminated, wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: University of Maryland, Baltimore | Conditions: Breast Cancer | NA | Status: TERMINATED | Results posted: 2026-04-15